Advanced Glycation End Products As Biomarkers for Cardiovascular Disease: Browning Clarifying Atherogenesis

References

• Fishman SL , SonmezH, BasmanC, SinghV, PoretskyL. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol. Med.24(1), 59 (2018).
   PubMed Web of Science ®Google Scholar
• Henning C , GlombMA. Pathways of the Maillard reaction under physiological conditions. Glycoconj. J.33(4), 499–512 (2016).
   PubMed Web of Science ®Google Scholar
• Nowotny K , SchröterD, SchreinerM, GruneT. Dietary advanced glycation end products and their relevance for human health. Ageing Res. Rev.47, 55–6657 (2018).
   PubMed Web of Science ®Google Scholar
• MacLean M , DerkJ, RuizHH, JuranekJK, RamasamyR, SchmidtAM. The receptor for advanced glycation end products (RAGE) and DIAPH1: implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system. Neurochem. Int.126, 154–164 (2019).
   PubMed Web of Science ®Google Scholar
• Guerin-Dubourg A , CournotM, PlanesseCet al. Association between fluorescent advanced glycation end-products and vascular complications in Type 2 diabetic patients. Biomed. Res. Int.2017, 7989180 (2017).
   PubMed Web of Science ®Google Scholar
• de la Cruz-Ares S , CardeloMP, Gutiérrez-MariscalFMet al. Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: from the CORDIOPREV study. Nutrients12(1), pii: E238 (2020).
   Web of Science ®Google Scholar
• Du R , ZhangRY, LuLet al. Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with Type 2 diabetes: an intravascular ultrasound study. Cardiovasc. Diabetol.17(1), 149 (2018).
   PubMedGoogle Scholar
• Hanssen NMJ , EngelenL, FerreiraIet al. Plasma levels of advanced glycation endproducts nepsilon-(carboxymethyl)ly- sine, nepsilon-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in indi-viduals with or without Type 2 diabetes: the Hoorn and CODAM studies. J. Clin. Endocrinol. Metab.98(8), E1369–E1373 (2013).
   PubMed Web of Science ®Google Scholar
• Busch M , FrankeS, WolfGet al. The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am. J. Kidney Dis.48(4), 571–579 (2006).
   PubMed Web of Science ®Google Scholar
• Yamagishi S , NakamuraK, MatsuiTet al. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investig. Drugs17(7), 983–996 (2008).
   PubMed Web of Science ®Google Scholar
• Nakamura T , TsujimotoT, YasudaKet al. Poorly controlled type 2 diabetes with no progression of diabetes-related complications and low levels of advanced glycation end products: a case report. Medicine98(30), e16573 (2019).
   PubMed Web of Science ®Google Scholar
• Sánchez E , BetriuÀ, YeramianAet al. Skin autofluorescence measurement in subclinical atheromatous disease: results from the ILERVAS project. J. Atheroscler. Thromb.26(10), 879–889 (2019).
   PubMed Web of Science ®Google Scholar
• Jujić A , ÖstlingG, PerssonMet al. Skin autofluorescence as a measure of advanced glycation end product levels is associated with carotid atherosclerotic plaque burden in an elderly population. Diab. Vasc. Dis. Res.16(5), 466–473 (2019).
   PubMed Web of Science ®Google Scholar
• Vergès B . Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam. Clin. Pharmacol.23(6), 681–685 (2009).
   PubMed Web of Science ®Google Scholar
• Wang HH , GarrutiG, LiuM, PortincasaP, WangDQ. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann. Hepatol.16(Suppl. 1), S27–S42 (2017).
   PubMedGoogle Scholar
• Kamtchueng SO , IkhlefS, BerrouguiH, KhalilA. Advanced glycation end products affect cholesterol homeostasis by impairing ABCA-1 expression on macrophages. Can. J. Physiol. Pharmacol.95(8), 977–984 (2017).
   PubMed Web of Science ®Google Scholar
• de Souza Pinto R , CastilhoG, PaimBAet al. Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids47(5), 443–450 (2012).
   PubMed Web of Science ®Google Scholar
• Okuda LS , CastilhoG, RoccoDD, NakandakareER, CatanoziS, PassarelliM. Advanced glycated albumin impairs HDL anti-inflammatory activity and primes macrophages for inflammatory response that reduces reverse cholesterol transport. Biochim. Biophys. Acta1821(12), 1485–92 (2012).
   PubMed Web of Science ®Google Scholar
• Castilho G , OkudaLS, PintoRSet al. ER stress is associated with reduced ABCA-1 protein levels in macrophages treated with advanced glycated albumin - reversal by a chemical chaperone. Int. J. Biochem. Cell Biol.44(7), 1078–1086 (2012).
   PubMed Web of Science ®Google Scholar
• Iborra RT , Machado-LimaA, CastilhoGet al. Advanced glycation in macrophages induces intracellular accumulation of 7-ketocholesterol and total sterols by decreasing the expression of ABCA-1 and ABCG-1. Lipids Health Dis.10, 172 (2011).
   PubMed Web of Science ®Google Scholar
• Iborra RT , Machado-LimaA, OkudaLSet al. AGE-albumin enhances ABCA-1 degradation by ubiquitin-proteasome and lysosomal pathways in macrophages. J. Diabetes Complications32(1), 1–10 (2018).
   PubMed Web of Science ®Google Scholar
• Machado-Lima A , IborraRT, PintoRSet al. Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCA-1-mediated reverse cholesterol transport. Diabetes Metab. Res. Rev.29(1), 66–76 (2013).
   PubMed Web of Science ®Google Scholar
• Machado-Lima A , IborraRT, PintoRSet al. In type 2 diabetes mellitus glycated albumin alters macrophage gene expression impairing ABCA1-mediated cholesterol efflux. J. Cell. Physiol.230(6), 1250–1257 (2015).
   PubMed Web of Science ®Google Scholar
• Pinto-Junior DC , SilvaKS, MichalaniMLet al. Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression. Sci. Rep.8(1), 8109 (2018).
   PubMedGoogle Scholar
• Okura T , UetaE, NakamuraRet al. High serum advanced glycation end products are associated with decreased insulin secretion in patients with type 2 diabetes: a brief report. J. Diabetes Res.2017, 5139750 (2017).
   PubMed Web of Science ®Google Scholar